Apple’s iOS 27 update focuses on faster performance, Siri AI, Liquid Glass controls, expanded Apple Intelligence, and new family safety tools. Apple’s iOS 27 looks less like a redesign and more like a ...

AI has taken the world by storm over the last few years, with millions of users writing prompts on platforms like ChatGPT to generate content, images, and yes videos. Still, some of these platforms ...

Need a process flow diagram? Get AI to build you one. Use Claude.ai with this special skill to generate professional process flow diagrams in seconds. Describe your workflow — manual steps, automated ...

Proteins are far more than nutrients we track on a food label. Present in every cell of our bodies, they work like nature's molecular machines. They walk, stretch, bend, and flex to do their jobs, ...

AI thrives on data but feeding it the right data is harder than it seems. As enterprises scale their AI initiatives, they face the challenge of managing diverse data pipelines, ensuring proximity to ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

The Random RNA Sequence Generator is a free online tool that helps researchers, bioinformaticians, and students create accurate synthetic genetic data. As molecular biology and computational genomics ...

The Random Sequence Generator is a free online tool designed to help you easily generate synthetic biological sequences, including DNA, RNA, and proteins. These sequences are applicable to a variety ...

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...